Gift-giving platform makes dreams and wishes come true

BPT - Young adventurer Yuval has always dreamt of exploring the world. In fact, travel is the #1 way he and his mother, Avital, bonded. However, he had to put his adventures on hold when he became sick.

When he was 7 years old, Yuval's mom found a lump on his neck that turned out to be lymphoma.

"I was heartbroken and lost," said Avital. "I couldn't take one breath of air without pain all over my body."

However, the brave little adventurer faced aggressive cancer treatment with determination. Today, there's no evidence of his disease. And he got to celebrate his travel wish with the help of Make-A-Wish and its donors.

Yuval's greatest wish was to ski and explore Alaska. He got to do that and more! During his adventure in the Alaskan wilderness, he not only skied but also snowmobiled, snowshoed and even had the opportunity to go dog sledding. Best of all, he got to do it all with his best friend, Chase. With this adventure under his belt, Yuval is ready to continue to explore more of the world around him and reclaim the time he lost when fighting illness.

Donors make dreams possible

Turning Yuval and other children's dreams into reality wouldn't be possible without the help of Make-A-Wish sponsors like Snappy. This year, Snappy - the leading gifting company - hit a huge milestone, donating $2 million to Make-A-Wish.

Snappy is an all-in-one gifting company that spreads joy, shares gratitude and takes the guesswork out of gifting. The company connects people and cultivates meaningful relationships through the power of gratitude and gifting. Its "recipient-picks" experience ensures gift-givers send the perfect gift every time, for everyone, on every occasion. It even allows recipients to donate the value of their gift to a charity of their choice.

Businesses can use the online platform to purchase gifts for employees, business partners, clients. It's these gift recipients who opted to donate the value of their gift to help support the transformative wishes of children with critical illnesses that have made Snappy's significant achievement possible.

"At Snappy, we are so grateful to witness the profound impact of individual generosity," said Hani Goldstein, Snappy co-founder and CEO. "When members of our community choose to donate their gift's value to Make-A-Wish, they create a cascade of positivity. The philanthropic potential of our platform has made us deeply thankful for the kindness of our gift recipients and the wishes they've made possible for these children and their families."

Wishes aren't just fun activities. When a child's wish is granted, it can create hope even in the most challenging situations.

"A wish creates an immediate turning point in a child's treatment and recovery, and partnerships like Snappy's make more of these life-changing wishes possible," said Leslie Motter, president and CEO of Make-A-Wish America. "There's a gap between the number of wishes we're granting and the number of wishes waiting, and we're thrilled for Snappy's support to help us close that gap."

This holiday season and beyond, help Make-A-Wish and Snappy fulfill more wishes while also finding meaningful gifts for those in your life. To learn more about how you can help make a child's wish come true, visit Wish.org.

---

Clinical trial for people who can't sleep with CPAP in progress

Photo: Quin Stevenson/Unsplash

BPT - If you are one of the more than 35 million Americans who are estimated to have obstructive sleep apnea (OSA), you already know how disruptive it can be to your life. While OSA is one of the most common and serious sleep disorders, the condition is widely under-diagnosed, so the number of affected Americans may be far greater.

What is obstructive sleep apnea?

OSA occurs when the muscles in the throat relax during sleep, blocking normal breathing. This can lead to low levels of oxygen in your blood while you sleep and result in poor sleep, fatigue and sleepiness that can negatively impact quality of life for many. In the long term, OSA has also been shown to contribute to high blood pressure, diabetes, cardiovascular disease and stroke.

Most people diagnosed with OSA are prescribed positive air pressure therapy devices such as continuous positive airway pressure, or CPAP, which can work very well in helping people receive the oxygen they need while they are sleeping. However, because many have difficulty using or tolerating these devices, a significant percentage of the population with OSA remains untreated, undertreated and at risk.

A new option for treating obstructive sleep apnea

Apnimed is a pharmaceutical company working to change the way OSA is treated. The company recently completed a large Phase 2b clinical trial, called MARIPOSA, to study AD109 (an investigational medication which is a single pill taken at bedtime) as a possible treatment for obstructive sleep apnea.

AD109 has the potential to be the first oral medication that treats both the underlying cause of OSA - airway obstruction at night - and improve the daytime symptoms of OSA, such as fatigue. It is designed to treat people with OSA from mild to severe.

Many patients with OSA are unable to adequately treat their condition with existing options, and the team at Apnimed is driven to find new solutions for patients and their doctors to overcome these barriers to treatment. The success of this effort is largely dependent on the dedicated work done by patients and doctors in the community who take part in clinical research.

"MARIPOSA results showed that AD109 improved daytime fatigue, which is an often debilitating effect of poor sleep due to OSA," said Paula Schweitzer, Ph.D., an investigator in the MARIPOSA trial and director of research at St. Luke's Sleep Medicine and Research Center, Chesterfield, Missouri. "For those who cannot tolerate current treatments, AD109 has the potential to be a convenient oral pill that could improve people's quality of life at night and during the daytime as well."

Learn about enrolling in the clinical trial

With the promising results from the MARIPOSA study, a new study is now available for people with OSA.

If you or a loved one has obstructive sleep apnea and you are unable to successfully use or tolerate treatment with a CPAP machine, you could be eligible to enroll in a six-month clinical trial called SynAIRgy.

To learn more about the clinical trial and to enroll, visit: www.SynAIRgyStudy.com.

---